Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Interactive Cardiovascular and Thoracic Surgery 2019-Nov

Postoperative outcomes of robotic-assisted lobectomy in obese patients with non-small-cell lung cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Le lien est enregistré dans le presse-papiers
Monica Casiraghi
Giulia Sedda
Cristina Diotti
Alessio Mariolo
Domenico Galetta
Adele Tessitore
Patrick Maisonneuve
Lorenzo Spaggiari

Mots clés

Abstrait

The aim of this study was to assess the postoperative outcomes of robotic-assisted lobectomy in obese patients to determine the impact of the robotic approach on a high-risk population who were candidates for major pulmonary resection for non-small-cell lung cancer (NSCLC).Between January 2007 and August 2018, we retrospectively reviewed the medical records of 224 obese patients (body mass index ≥ 30) who underwent pulmonary lobectomy at our institution via robotic-assisted thoracic surgery (RATS, n = 51) or lateral muscle-sparing thoracotomy (n = 173).Forty-two patients were individually matched with those who had the same pathological tumour stage and similar comorbidities and presurgical treatment. The median operative time was significantly longer in the RATS group compared to that in the thoracotomy group (200 vs 158 min; P = 0.003), whereas the length of stay was significantly better for the RATS group (5 vs 6 days; P = 0.047). Postoperative complications were significantly more frequent after open lobectomy than in the RATS group (42.9% vs 16.7%; P = 0.027). After a median follow-up of 4.4 years, the 5-year overall survival rate was 67.6% [95% confidence interval (CI) 45.7-82.2] for the RATS group, and 66.1% (95% CI 46.8-79.9) for the open surgery group (log-rank P = 0.54). The 5-year cumulative incidence of cancer-related deaths was 24.8% (95% CI 9.7-43.5) for the RATS group and 23.6% (95% CI 10.8-39.2) for the open surgery group (Gray's test, P = 0.69).RATS is feasible and safe for obese patients with NSCLC with advantages compared to open surgery in terms of early postoperative outcomes. In addition, the long-term survival rate was comparable to that of the open approach.

Rejoignez notre
page facebook

La base de données d'herbes médicinales la plus complète soutenue par la science

  • Fonctionne en 55 langues
  • Cures à base de plantes soutenues par la science
  • Reconnaissance des herbes par image
  • Carte GPS interactive - étiquetez les herbes sur place (à venir)
  • Lisez les publications scientifiques liées à votre recherche
  • Rechercher les herbes médicinales par leurs effets
  • Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées

Google Play badgeApp Store badge